International Journal of Experimental Dental Science

Register      Login

VOLUME 3 , ISSUE 2 ( July-December, 2014 ) > List of Articles

RESEARCH ARTICLE

B-Cell Activating Factor Levels in Saliva and Serum before and after Treatment of Oral Infections

Umit Karacayli, Neslihan Yilmaz, Muge Bicakcigil, Hale Cimilli, Sule Yavuz, Gonca Mumcu

Citation Information : Karacayli U, Yilmaz N, Bicakcigil M, Cimilli H, Yavuz S, Mumcu G. B-Cell Activating Factor Levels in Saliva and Serum before and after Treatment of Oral Infections. Int J Experiment Dent Sci 2014; 3 (2):63-66.

DOI: 10.5005/jp-journals-10029-1073

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2014; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background

B-cell activating factor belonging to the TNF family (BAFF) levels may increase in response to oral infections. The aim of the study was to evaluate saliva and serum BAFF levels in patients with oral infection and to monitor them after dental treatments.

Materials and methods

Fifteen patients with an oral infection foci including pericoronitis (n = 7) and irreversible pulpitis (n = 8) (F/M:10/5 mean age: 39.8 ± 7.2 years) were selected for the study. All patients were examined pretreatment period immediately and a week after endodontic treatment or oral surgical treatment. Unstimulated saliva and serum samples were collected from patients in these periods. Salivary and serum BAFF levels were measured by ELISA method (Bender, Medsystems, Viena, Austria).

Results

Since BAFF levels were similar in patients with irreversible pulpitis and pericoronitis (p > 0.05), two groups were combined in the study. Pretreatment salivary (median: 7.09 ng/ml) and serum BAFF levels (3.28 ng/ml) were significantly decreased after elimination of infection focus by endodontic or oral surgical treatments (0.37 vs 0.0) (p = 0.028 and 0.002). Saliva and serum BAFF levels were not correlated in preand post-treatment periods (p > 0.05).

Conclusion

Salivary and serum BAFF levels of patients with oral infections could be decreased by endodontic or oral surgical treatments.

How to cite this article

Karacayli U, Yilmaz N, Bicakcigil M, Cimilli H, Yavuz S, Mumcu G. B-Cell Activating Factor Levels in Saliva and Serum before and after Treatment of Oral Infections. Int J Experiment Dent Sci 2014;3(2):63-66.


PDF Share
  1. The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 2005; 8:206-242.
  2. BAFF: a fundamental survival factor for B-cells. Nat Rev Immunol 2002;2(7):465-475.
  3. BAFF and APRIL: a tutorial on B-cell survival. Annu Rev Immunol 2003; 21:231-264.
  4. Functional and clinical aspects of the B-cellactivating factor (BAFF): a narrative review. Scand J Immunol 2011;73(1):1-7.
  5. BAFF and the regulation of B-cell survival. Immunol Lett 2003;88(1):57-62.
  6. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10(4):R97.
  7. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48(4): 982-992.
  8. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109(1):59-68.
  9. New ELISA for B-cell activating factor. Clin Chem 2009;55(10):1843-1851.
  10. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren's syndrome. Oral Health Prev Dent 2013;11(3):229-234.
  11. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005;174(9):5537-5544.
  12. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006;112(3):774-786.
  13. Methods in Molecular Biology, The ELISA Guidebook, Vol. 516© Humana Press, a part of Springer Science + Business Media, LLC 2009.
  14. BAFF modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007;56(5):1464-1477.
  15. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int 2011;31(8):1045-1049.
  16. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90(5):600-608.
  17. Spinal abscess and mitral valve endocarditis secondary to asymptomatic fusobacteriuminduced dental abscess. J R Soc Med 2006;99(7):368-369.
  18. The role of unfinished root canal treatment in odontogenic maxillofacial infections requiring hospital care. Clin Oral Investig 2012 Mar 14 [Epub ahead of print].
  19. Predisposing factors of complicated deep neck infection: an analysis of 158 cases. Yonsei Med J 2007;48(1):55-62.
  20. Role of TNF-alpha and its receptors in pericoronitis. J Dent Res 2005;84(12):1178-1182.
  21. Irreversible but not reversible pulpitis is associated with upregulation of tumour necrosis factor-alpha gene expression in human pulp. Int Endod J 2007;40(3):198-203.
  22. Salivary levels of human neutrophil peptides 1-3 are related to oral ulcer activity in Behcet's disease. Int J Dermatol 2013 Oct;52(10):1198-1201.
  23. Factors affecting wound healing. J Dent Res 2010;89(3):219-229.
  24. Inflammatory and immunological aspects of dental pulp repair. Pharmacol Res 2008;58(2):137-147.
  25. Side effects and complications associated with third molar surgery. Oral Surg Oral Med Oral Pathol 1993 Oct;76(4):412-420.
  26. Influence of two different flap designs on incidence of pain, swelling, trismus, and alveolar osteitis in the week following third molar surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 July;104(1):e1-e6.
  27. A clinical and microbiological study to evaluate the effect of dietary supplement of coenzyme Q10 in nonsurgical treatment outcome of chronic periodontitis patients after phase 1 periodontal therapy. Eur J Gen Dent 2014;3:194-198.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.